田口 和明 (タグチ カズアキ)

Taguchi, Kazuaki

写真a

所属(所属キャンパス)

薬学部 薬学科 薬効解析学講座 (芝共立)

職名

専任講師

経歴 【 表示 / 非表示

  • 2010年04月
    -
    2011年03月

    日本学術振興会特別研究員

  • 2011年04月
    -
    2013年03月

    熊本大学医学部附属病院, 薬剤部, 薬剤師

  • 2013年04月
    -
    2017年03月

    崇城大学 , 薬学部, 助教

  • 2018年04月
    -
    継続中

    慶應義塾大学, 薬学部, 専任講師

学歴 【 表示 / 非表示

  • 2006年03月

    熊本大学, 薬学部

    大学, 卒業

  • 2008年03月

    熊本大学

    大学院, 修了, 博士前期

  • 2011年03月

    熊本大学

    大学院, 修了, 博士後期

学位 【 表示 / 非表示

  • 博士 (薬学), 熊本大学, 2011年03月

免許・資格 【 表示 / 非表示

  • 薬剤師, 2006年04月

 
 

著書 【 表示 / 非表示

  • DDS先端技術の製剤への応用開発

    宗慶太郎, 田口和明, 技術情報協会, 2017年

    担当範囲: 第6章6節 pp. 360-8

  • Human Serum Albumin (HSA): Functional Structure, Synthesis and Therapeutic Uses

    Taguchi K, Chuang VT, Yamasaki K, Otagiri M., Nova Science Publishers, Inc., 2015年

    担当範囲: Chapter 4, pp. 69-89

  • HUMAN SERUM ALBUMIN

    Taguchi K, Chuang VT, Otagiri M., 2013年

    担当範囲: Chapter 20, pp. 401-15

  • Acute Phase Proteins

    Taguchi K, Nishi K, Chuang VT, Maruyama T, Otagiri M., Intech, 2013年

    担当範囲: Chapter 6, pp.139-62

論文 【 表示 / 非表示

  • Evasion of the accelerated blood clearance phenomenon by polysarcosine coating of liposomes

    Son K., Ueda M., Taguchi K., Maruyama T., Takeoka S., Ito Y.

    Journal of Controlled Release (Journal of Controlled Release)  322   209 - 216 2020年06月

    ISSN  01683659

     概要を見る

    © 2020 Elsevier B.V. Using polyethylene glycol (PEG) to functionalize liposomes improves their stealth properties and stability in blood. However, PEG is known to induce the accelerated blood clearance (ABC) phenomenon, which occurs for multiple doses owing to anti-PEG IgM being produced after the initial injection. In this study, as an alternative to PEG, polysarcosine (PSar) was selected owing to its low antigenicity and its highly dense chains with controllable lengths, similar to PEG. Furthermore, we directly evaluate the potential of PSar for avoiding the ABC phenomenon by comparing PSar with PEG on the same liposome platform, which has similar physicochemical properties such as hydrophobic region, membrane fluidity, and size. PEG- and PSar-liposomes were prepared and characterized for comparison. PSar-liposomes showed similar physicochemical properties to PEG-liposomes in terms of size control, zeta potential, membrane polarity, and fluidity; however, ELISA results showed noticeably lower levels and faster production speeds of both IgM and IgG for PSar-liposomes than for PEG-liposomes. In addition, a pharmacokinetics experiment with multiple injections showed that PSar-PE coating of liposomes may help to circumvent the ABC phenomenon.

  • Effects of arterial hemorrhage speed on the blood coagulation/fibrinolysis system and hemodynamics in rats

    Furukawa S., Sasao A., Yonemitsu K., Ohtsu Y., Tsutsumi H., Taguchi K., Otagiri M., Nishitani Y.

    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis (Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis)  31 ( 3 ) 198 - 206 2020年04月

     概要を見る

    : The effects of rapid hemorrhage on coagulopathy have been reported. However, the effects of different hemorrhage speeds on the blood coagulation/fibrinolysis system have not been investigated. This study aimed to compare different hemorrhage speeds for clarifying their effects on the coagulation/fibrinolysis system and circulation disorders in rats. Male Sprague-Dawley rats (301-396 g) were randomly assigned to five groups depending on hemorrhage speed and length of procedure: first, rapid (1.4 ml/min, 30-min bleeding); second, rapid-L (1.4 ml/min, 30-min bleeding and observation until 6 h); third, slow (0.1 ml/min, intermittently, 6-h bleeding); fourth, control (30-min observation); and fifth, control-L (6-h observation). Hemorrhage was induced by withdrawing blood until 40% of the estimated blood volume from the femoral artery. We measured vital signs, hematology, general chemistry, blood gas status, coagulation parameters, fibrinolytic markers [tissue-type plasminogen activator and plasminogen activator inhibitor one (PAI-1)], vascular endothelial damage (syndecan-1), and liver PAI-1 mRNA expression. Rapid hemorrhage induced elevation of lactate and syndecan-1 levels and prolonged prothrombin time and activated partial thromboplastin time in the rapid group. In contrast, slow hemorrhage did not induce these changes. Hemorrhage speed had no effect on plasma tissue-type plasminogen activator and hematology. Plasma PAI-1 levels were significantly increased in the rapid-L group, while liver PAI-1 mRNA levels were increased in the slow group. This study shows changes in the circulatory and fibrinolysis systems, depending on the hemorrhage speed. Hemorrhage might promote production of PAI-1, while tissue hypoxia due to rapid hemorrhage might promote release of PAI-1.

  • Processing grapefruit juice with γ-cyclodextrin attenuates its inhibitory effect on cytochrome P450 3A activity

    Yamasaki K., Iohara D., Oyama Y., Nishizaki N., Kawazu S., Nishi K., Kadowaki D., Taguchi K., Otagiri M., Seo H.

    Journal of Pharmacy and Pharmacology (Journal of Pharmacy and Pharmacology)  72 ( 3 ) 356 - 363 2020年03月

    ISSN  00223573

     概要を見る

    © 2019 Royal Pharmaceutical Society Objectives: Grapefruit (Citrus paradisi) juice enhances the oral bioavailability of drugs that are metabolized by intestinal cytochrome P450 3A4 (CYP3A4). Patients are advised to avoid drinking grapefruit juice to prevent this drug–grapefruit juice interaction. The aim of this study was to investigate whether processing grapefruit juice with cyclodextrins (CDs) would result in preventing or inhibiting this interaction. Methods: Grapefruit juice and the major furanocoumarins found in grapefruit, bergamottin (BG) and 6′, 7′-dihydroxy bergamottin (DHBG) were mixed with α, β and γCDs. The effects of these processed juice samples and furanocoumarins on CYP3A activity were compared with the corresponding values for unprocessed juices and furanocoumarins. Interactions between CDs and these furanocoumarins were also investigated by phase solubility and 1H NMR studies. Key findings: The inhibition of CYP3A by grapefruit juice was significantly attenuated by processing particularly with γCD. Similar attenuation effects by γCD were observed in the cases of BG and DHBG. Furthermore, BG and DHBG were suggested to be strongly encapsulated in the cavity of γCD. Conclusion: The encapsulation of BG and DHBG by γCD and the resulting attenuation of the inhibition of CYP3A activity by grapefruit juice may be applicable to juice processing for preventing drug-grapefruit juice interactions.

  • Carbon monoxide rescues the developmental lethality of experimental rat models of rhabdomyolysis-induced acute kidney injury

    Taguchi K., Ogaki S., Nagasaki T., Yanagisawa H., Nishida K., Maeda H., Enoki Y., Matsumoto K., Sekijima H., Ooi K., Ishima Y., Watanabe H., Fukagawa M., Otagiri M., Maruyama T.

    Journal of Pharmacology and Experimental Therapeutics (Journal of Pharmacology and Experimental Therapeutics)  372 ( 3 ) 355 - 365 2020年03月

    ISSN  00223565

     概要を見る

    © 2020 by The American Society for Pharmacology and Experimental Therapeutics Many victims, after being extricated from a collapsed building as the result of a disaster, suffer from disaster nephrology, a term that is referred to as the crush syndrome (CS). Recommended treatments, which include dialysis or the continuous administration of massive amounts of fluid are not usually easy in cases of such mass natural disasters. In the present study, we examined the therapeutic performance of a biomimetic carbon monoxide (CO) delivery system, CO-enriched red blood cells (CO-RBCs), on experimental animal models of an acute kidney injury (AKI) induced by traumatic and nontraumatic rhabdomyolysis, including CS and rhabdomyolysis with massive hemorrhage shock. A single CO-RBC treatment was found to effectively suppress the pathogenesis of AKI with the mortality in these model rats being improved. In addition, in further studies using glycerol-induced rhabdomyolysis model rats, the pathogenesis of which is similar to that for the CS, AKI and mortality were also reduced as the result of a CO-RBC treatment. Furthermore, CO-RBCs were found to have renoprotective effects via the suppression of subsequent heme protein-associated renal oxidative injury; the oxidation of myoglobin in the kidneys, the generation of reactive oxygen species by free heme produced from degraded-cytochrome P450 and hemoglobin-associated renal injury. Because CO-RBCs can be prepared and used at both hospitals and at a disaster site, these findings suggest that CO-RBCs have the potential for use as a novel cell therapy against both nontraumatic and traumatic rhabdomyolysis including CS-induced AKI.

  • Strategy of drug development based on the bioactive gas-carrying capacity of hemoglobin

    Taguchi K., Matsumoto K., Maruyama T., Otagiri M.

    Yakugaku Zasshi (Yakugaku Zasshi)  140 ( 2 ) 141 - 146 2020年02月

    ISSN  00316903

     概要を見る

    © 2020 The Pharmaceutical Society of Japan. Bioactive gas molecules, including oxygen, nitric oxide and carbon monoxide (CO), exhibit a variety of physiological activities, and are associated with the onset and progress of some disorders. These facts have led researchers to the development of bioactive gas donors for the treatment of intractable disorders. Hemoglobin is likely an ideal carrier of bioactive gases, since hemoglobin in red blood cells innately carries oxygen in the form of oxyhemoglobin, nitric oxide in the form of S-nitrosohemoglobin, and CO in the form of carbonylhemoglobin. In this study, we attempted to develop a biomimetic CO delivery system using a preparation of hemoglobin. Our strategy for the preparation of this hemoglobin-based CO carrier involves CO being exogenously bound to red blood cells or hemoglobin-encapsulated liposomes, called hemoglobin-vesicles (HbV), which mimic the structure and function of red blood cells. We accumulated evidence that the CO donors-CO-bound red blood cells and CO-bound HbV-showed therapeutic efficacy against intractable disorders in animal models. Here, we describe the potential of hemoglobin-based CO donors, especially CO-bound red blood cells and CO-bound HbV, for the treatment of certain disorders. Hemoglobin-based strategies for the delivery of other bioactive gases for novel drug development are also discussed.

全件表示 >>

総説・解説等 【 表示 / 非表示

  • The charm of protein for drug development

    Ishima Y., Taguchi K.

    Yakugaku Zasshi (Yakugaku Zasshi)  140 ( 2 ) 139 - 140 2020年02月

    ISSN  00316903

  • 細胞型人工赤血球の動態特性解析に基づく安全性評価と医療ガスデリバリーへの応用

    田口 和明

    薬学雑誌 138   1381 - 1389 2018年

    総説・解説(学術雑誌), 単著

  • The use of Hemoglobin vesicles for delivering medicinal gas for the treatment of intractable disorders.

    Taguchi K, Yamasaki K, Sakai H, Maruyama T, Otagiri M.

    J Pharm Sci. 106 ( 9 ) 2392 - 2400 2017年

    総説・解説(学術雑誌), 共著

  • Comparison of the pharmacokinetic properties of hemoglobin-based oxygen carriers.

    Taguchi K, Yamasaki K, Maruyama T, Otagiri M.

    J Funct Biomater. 8 ( 1 ) E11 2017年

    総説・解説(学術雑誌), 共著

  • Potential use of biological proteins for liver failure therapy.

    Taguchi K, Yamasaki K, Seo H, Otagiri M.

    Pharmaceutics. 7 ( 3 ) 255 - 274 2015年

    総説・解説(学術雑誌), 共著

全件表示 >>

競争的資金等の研究課題 【 表示 / 非表示

  • 震災特有疾患に対する一酸化炭素結合型ヘモグロビン小胞体の医薬品としての有用性評価

    2017年04月
    -
    2020年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 田口 和明, 基盤研究(C), 補助金,  代表

受賞 【 表示 / 非表示

  • 熊本大学学長賞

    2011年03月

  • 日本薬学会九州支部学術奨励賞

    2017年12月

  • 日本薬学会奨励賞

    2020年03月

    受賞区分: 国内学会・会議・シンポジウム等の賞

 

担当授業科目 【 表示 / 非表示

  • 課題研究(薬効解析学)

    2020年度

  • 演習(薬効解析学)

    2020年度

  • 卒業研究1(薬学科)

    2020年度

  • 実務実習事前学習1

    2020年度

  • 実務実習事前学習(実習)

    2020年度

全件表示 >>